Significantly Decreased Mortality in a Large Cohort of Coronavirus Disease 2019 (COVID-19) Patients Transfused Early with Convalescent Plasma Containing High-Titer Anti–Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Spike Protein IgG

Treatment of COVID-19 Patients with Convalescent Plasma

(2020) Eric Salazar et al.   AMERICAN JOURNAL OF PATHOLOGY

The convalescent sera option for containing COVID-19

(2020) Arturo Casadevall et al.   JOURNAL OF CLINICAL INVESTIGATION

Convalescent plasma to treat coronavirus disease 2019 (COVID‐19): considerations for clinical trial design

(2020) Paul Barone et al.   TRANSFUSION

Treatment of COVID-19 Patients with Convalescent Plasma Reveals a Signal of Significantly Decreased Mortality

(2020) Eric Salazar et al.   AMERICAN JOURNAL OF PATHOLOGY

Use of convalescent plasma in hospitalized patients with COVID-19: case series

(2020) Livia Hegerova et al.   BLOOD

Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19

(2020) Ling Li et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Evaluating the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in severely ill adults with COVID-19: A structured summary of a study protocol for a randomized controlled trial

(2020) Christina M. Eckhardt et al.   Trials

Convalescent plasma treatment of severe COVID-19: a propensity score–matched control study

(2020) Sean T. H. Liu et al.   NATURE MEDICINE

Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial)

(2020) Anup Agarwal et al.   BMJ-British Medical Journal

Convalescent plasma anti–SARS-CoV-2 spike protein ectodomain and receptor-binding domain IgG correlate with virus neutralization

(2020) Eric Salazar et al.   JOURNAL OF CLINICAL INVESTIGATION